Does the media refer more to ELAN or GPCR?

In the previous week, Elanco Animal Health had 2 more articles in the media than Structure Therapeutics. MarketBeat recorded 4 mentions for Elanco Animal Health and 2 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.87 beat Elanco Animal Health's score of 1.31 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor ARWR or GPCR?

In the previous week, Arrowhead Pharmaceuticals had 8 more articles in the media than Structure Therapeutics. MarketBeat recorded 10 mentions for Arrowhead Pharmaceuticals and 2 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.87 beat Arrowhead Pharmaceuticals' score of 0.99 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 4 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer GPCR or RDY?

Structure Therapeutics currently has a consensus target price of $110.55, suggesting a potential upside of 105.97%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Structure Therapeutics is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Structure Therapeutics 2 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 3 Strong Buy rating(s) 2.89 Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media prefer GPCR or RDY?

In the previous week, Structure Therapeutics and Structure Therapeutics both had 2 articles in the media. Structure Therapeutics' average media sentiment score of 1.87 beat Dr. Reddy's Laboratories' score of -0.23 indicating that Structure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Dr. Reddy's Laboratories 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, GPCR or SMMT?

Structure Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Structure Therapeutics N/A N/A -$141.20M -$0.87 N/A Summit Therapeutics N/A N/A -$1.08B -$1.60 N/A

Is GPCR or SMMT more profitable?

Structure Therapeutics' return on equity of -24.91% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Structure Therapeutics N/A -24.91% -23.67% Summit Therapeutics N/A -291.24% -243.07%

Does the media prefer GPCR or SMMT?

In the previous week, Structure Therapeutics and Structure Therapeutics both had 2 articles in the media. Structure Therapeutics' average media sentiment score of 1.87 beat Summit Therapeutics' score of 1.81 indicating that Structure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Summit Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer GPCR or KRYS?

In the previous week, Krystal Biotech had 7 more articles in the media than Structure Therapeutics. MarketBeat recorded 9 mentions for Krystal Biotech and 2 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.87 beat Krystal Biotech's score of 0.57 indicating that Structure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Krystal Biotech 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Structure Therapeutics (GPCR) Competitors

$53.67 +1.98 (+3.83%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$55.25 +1.58 (+2.94%)

As of 05:41 AM Eastern

Compare

GPCR vs. ELAN, ARWR, RDY, SMMT, and KRYS

Should you buy Structure Therapeutics stock or one of its competitors? MarketBeat compares Structure Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Structure Therapeutics include Elanco Animal Health (ELAN), Arrowhead Pharmaceuticals (ARWR), Dr. Reddy's Laboratories (RDY), Summit Therapeutics (SMMT), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry.

How does Structure Therapeutics compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

In the previous week, Elanco Animal Health had 2 more articles in the media than Structure Therapeutics. MarketBeat recorded 4 mentions for Elanco Animal Health and 2 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.87 beat Elanco Animal Health's score of 1.31 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Structure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Elanco Animal Health has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.35, meaning that its stock price is 235% less volatile than the broader market.

Structure Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Structure Therapeutics	N/A	-24.91%	-23.67%

Elanco Animal Health currently has a consensus target price of $28.55, indicating a potential upside of 15.87%. Structure Therapeutics has a consensus target price of $110.55, indicating a potential upside of 105.97%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by insiders. Comparatively, 5.5% of Structure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Structure Therapeutics has lower revenue, but higher earnings than Elanco Animal Health. Structure Therapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.61	-$232M	-$0.50	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A

Summary

Elanco Animal Health and Structure Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Structure Therapeutics compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

In the previous week, Arrowhead Pharmaceuticals had 8 more articles in the media than Structure Therapeutics. MarketBeat recorded 10 mentions for Arrowhead Pharmaceuticals and 2 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.87 beat Arrowhead Pharmaceuticals' score of 0.99 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Structure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Arrowhead Pharmaceuticals currently has a consensus price target of $87.27, suggesting a potential upside of 7.07%. Structure Therapeutics has a consensus price target of $110.55, suggesting a potential upside of 105.97%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Structure Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 5.5% of Structure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Arrowhead Pharmaceuticals has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.35, suggesting that its stock price is 235% less volatile than the broader market.

Structure Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Structure Therapeutics' return on equity of -24.91% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
Structure Therapeutics	N/A	-24.91%	-23.67%

Arrowhead Pharmaceuticals has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	13.84	-$1.63M	-$2.15	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A

Summary

Structure Therapeutics beats Arrowhead Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Structure Therapeutics compare to Dr. Reddy's Laboratories?

Structure Therapeutics (NASDAQ:GPCR) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 5.5% of Structure Therapeutics shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Structure Therapeutics and Structure Therapeutics both had 2 articles in the media. Structure Therapeutics' average media sentiment score of 1.87 beat Dr. Reddy's Laboratories' score of -0.23 indicating that Structure Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Dr. Reddy's Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Structure Therapeutics currently has a consensus target price of $110.55, suggesting a potential upside of 105.97%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Structure Therapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Structure Therapeutics has a beta of -1.35, meaning that its stock price is 235% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

Dr. Reddy's Laboratories has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A
Dr. Reddy's Laboratories	$3.58B	3.38	$456M	$0.58	25.01

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Structure Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%

Summary

Dr. Reddy's Laboratories beats Structure Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Structure Therapeutics compare to Summit Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Structure Therapeutics and Structure Therapeutics both had 2 articles in the media. Structure Therapeutics' average media sentiment score of 1.87 beat Summit Therapeutics' score of 1.81 indicating that Structure Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Summit Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Structure Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

Structure Therapeutics has a beta of -1.35, indicating that its stock price is 235% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.32, indicating that its stock price is 232% less volatile than the broader market.

Structure Therapeutics' return on equity of -24.91% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Summit Therapeutics	N/A	-291.24%	-243.07%

Structure Therapeutics presently has a consensus price target of $110.55, suggesting a potential upside of 105.97%. Summit Therapeutics has a consensus price target of $26.97, suggesting a potential upside of 85.13%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Structure Therapeutics is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44

91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 5.5% of Structure Therapeutics shares are held by insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Structure Therapeutics beats Summit Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Structure Therapeutics compare to Krystal Biotech?

Structure Therapeutics (NASDAQ:GPCR) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Krystal Biotech has a net margin of 53.92% compared to Structure Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Krystal Biotech	53.92%	19.25%	17.62%

Structure Therapeutics has a beta of -1.35, indicating that its share price is 235% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 5.5% of Structure Therapeutics shares are held by company insiders. Comparatively, 13.1% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Krystal Biotech had 7 more articles in the media than Structure Therapeutics. MarketBeat recorded 9 mentions for Krystal Biotech and 2 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.87 beat Krystal Biotech's score of 0.57 indicating that Structure Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Krystal Biotech	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A
Krystal Biotech	$389.13M	28.16	$204.83M	$7.48	49.69

Structure Therapeutics currently has a consensus target price of $110.55, suggesting a potential upside of 105.97%. Krystal Biotech has a consensus target price of $340.56, suggesting a potential downside of 8.37%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Structure Therapeutics is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Krystal Biotech beats Structure Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Structure Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GPCR vs. The Competition

Export

Metric	Structure Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.67B	$3.66B	$7.07B	$12.45B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-61.69	20.90	27.27	24.87
Price / Sales	N/A	341.80	544.68	102.84
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	2.15	8.75	10.95	6.54
Net Income	-$141.20M	$23.81M	$3.57B	$336.70M
7 Day Performance	11.44%	3.60%	2.29%	2.81%
1 Month Performance	39.22%	3.72%	1.36%	0.58%
1 Year Performance	161.68%	68.80%	36.68%	31.29%

Structure Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GPCR Structure Therapeutics	2.5908 of 5 stars	$53.67 +3.8%	$110.55 +106.0%	+158.8%	$3.67B	N/A	N/A	136	Positive News
ELAN Elanco Animal Health	3.764 of 5 stars	$23.91 -1.3%	$28.55 +19.4%	+72.4%	$12.10B	$4.72B	N/A	9,400	Analyst Forecast
ARWR Arrowhead Pharmaceuticals	2.0114 of 5 stars	$82.00 +0.2%	$86.36 +5.3%	+415.9%	$11.52B	$829.45M	N/A	400	Analyst Forecast
RDY Dr. Reddy's Laboratories	1.7067 of 5 stars	$13.91 +4.7%	N/A	-3.5%	$11.09B	$3.58B	23.99	27,527	High Trading Volume
SMMT Summit Therapeutics	3.981 of 5 stars	$14.28 +3.9%	$27.23 +90.7%	-31.5%	$10.67B	N/A	N/A	110	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GPCR) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Structure Therapeutics (GPCR) Competitors

GPCR vs. ELAN, ARWR, RDY, SMMT, and KRYS

How does Structure Therapeutics compare to Elanco Animal Health?

Summary

How does Structure Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Structure Therapeutics compare to Dr. Reddy's Laboratories?

Summary

How does Structure Therapeutics compare to Summit Therapeutics?

Summary

How does Structure Therapeutics compare to Krystal Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GPCR vs. The Competition

Structure Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Structure Therapeutics (GPCR) Competitors

GPCR vs. ELAN, ARWR, RDY, SMMT, and KRYS

How does Structure Therapeutics compare to Elanco Animal Health?

Does the media refer more to ELAN or GPCR?

Which has more risk & volatility, ELAN or GPCR?

Is ELAN or GPCR more profitable?

Do analysts prefer ELAN or GPCR?

Do insiders and institutionals believe in ELAN or GPCR?

Which has stronger earnings & valuation, ELAN or GPCR?

Summary

How does Structure Therapeutics compare to Arrowhead Pharmaceuticals?

Does the media favor ARWR or GPCR?

Do analysts prefer ARWR or GPCR?

Do insiders & institutionals hold more shares of ARWR or GPCR?

Which has more risk and volatility, ARWR or GPCR?

Is ARWR or GPCR more profitable?

Which has stronger earnings & valuation, ARWR or GPCR?

Summary

How does Structure Therapeutics compare to Dr. Reddy's Laboratories?

Do insiders and institutionals have more ownership in GPCR or RDY?

Does the media prefer GPCR or RDY?

Do analysts prefer GPCR or RDY?

Which has more risk & volatility, GPCR or RDY?

Which has preferable valuation & earnings, GPCR or RDY?

Is GPCR or RDY more profitable?

Summary

How does Structure Therapeutics compare to Summit Therapeutics?

Does the media prefer GPCR or SMMT?

Which has stronger earnings and valuation, GPCR or SMMT?

Which has more volatility & risk, GPCR or SMMT?

Is GPCR or SMMT more profitable?

Do analysts prefer GPCR or SMMT?

Do insiders & institutionals have more ownership in GPCR or SMMT?

Summary

How does Structure Therapeutics compare to Krystal Biotech?

Is GPCR or KRYS more profitable?

Which has more volatility and risk, GPCR or KRYS?

Do institutionals and insiders have more ownership in GPCR or KRYS?

Does the media prefer GPCR or KRYS?

Which has better valuation and earnings, GPCR or KRYS?

Do analysts rate GPCR or KRYS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GPCR vs. The Competition

Structure Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools